Q-omics provides the consensus-scored FADS2B profile across patient tissues and cancer cell-line models. FADS2B expression is associated with patient survival in 14 of 34 cancer types, with the highest sampling consensus in LUSC. Among the 18 cancer types available for tumor–normal comparison, FADS2B is differentially expressed in 7, with the highest sampling consensus in COAD. Additionally, FADS2B RNA expression shows 5,724 significant pathway-activity associations, with the highest sampling consensus in UCEC. Together, these results highlight LUSC, COAD, and UCEC as cancer lineages where FADS2B shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for FADS2B — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes FADS2B survival associations across molecular data types. FADS2B RNA expression shows survival associations in the most cancer types (14). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible FADS2B RNA expression–survival associations across cancer types. High FADS2B expression shows unfavorable associations in LUSC, BRCA, KIRC, KIRP, CESC and THYM. The LUSC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p = .003). Together, the overview and detailed table identify LUSC as the clearest survival context for FADS2B RNA expression.
This table summarizes FADS2B tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 7. The strongest signals are observed in COAD for RNA.
This table ranks reproducible tumor–normal expression differences for FADS2B. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. FADS2B shows lower tumor expression in COAD, LUAD and KIRC and higher tumor expression in HNSC, BRCA and STAD. The COAD box plot shows higher FADS2B RNA expression in normal versus tumor tissue (log2 FC = −0.167, t-test p < 0.001).
This table shows molecular features associated with FADS2B in patient tissues and cancer cell lines. In patient samples, FADS2B shows the broadest associations at the RNA and protein expression levels, with UCEC recurring as the lineage with the largest associated feature set.
